TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15 - 30 years~* Anorexia nervosa by psychiatric criteria~* Amenorrhea for at least 3 months~Exclusion Criteria:~* Receiving no medications known to affects bone metabolism~* No other chronic medical conditions

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo (sugar pill); identical to treatment medication capsule
- DHEA + Hormone replacement therapy (estrogen/progestin) (Type: EXPERIMENTAL): Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (\> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Oxidative Stress in Children With Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Autistic Disorder by DSM-IV 299.0 or CARS score \>30~Exclusion Criteria:~* Primary genetic disease with co-morbid autism~* frequent seizures~* recent surgery~* active infection with fever~* high dose vitamin/mineral supplements~* severe gastrointestinal symptoms

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Methyl B12 (Type: EXPERIMENTAL): Subcutaneous injection of 75 micrograms/Kg
- Folinic Acid (Type: EXPERIMENTAL): 400 micrograms orally twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Overweight but otherwise in good general health.~2. Age 18 - 55 years.~3. Normal glucose tolerance.~4. Stable weight with BMI (27-44).~5. Stable medication use for the preceding month.~6. BP \< 150/90.~7. Negative pregnancy test (\*HCG), if female and of childbearing potential.~8. Practicing, and willing to continue to practice appropriate contraception throughout the study if a female of childbearing potential.~Exclusion Criteria:~1. Serious medical illness.~2. Pregnancy.~3. Tobacco use within the past 6 months.~4. Prior or current treatment with a thiazolidinedione.~5. Patients who have received an investigational drug in the past 30 days.~6. Use of systemic corticosteroids.~7. Known or suspected allergy to Rosiglitazone or any component of the preparation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Rosiglitazone (Type: EXPERIMENTAL): One 8mg capsule daily for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): One capsule daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Greater Trochanteric Pain Syndrome: Efficacy of Ultrasound Guided Platelet-rich Plasma vs Needle Tenotomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both sexes between the ages of 35 and 75 years.~* At the screening visit, they present hip pain at 3 points out of 10 in EVA.~* Body Mass Index values between 20 and 35 (both values included).~* Commitment to comply with all study procedures.~* Diagnoses of chronic GTPS according to the diagnostic criteria that have been previously described.~* The patient must give written informed consent.~* Women of child-bearing age must obtain a negative test result of pregnancy in blood or urine and accept the use of appropriate contraception while in the trial.~Exclusion Criteria:~* • Body Mass Index\>35.~  * Presence of full tendon tear.~ * Systemic autoimmune rheumatologic disease (connective tissue diseases and systemic necrotizing vasculitis)~ * Poorly controlled diabetes mellitus (glycosylated hemoglobin above 9%)~ * Blood disorders (thrombopathy, thrombocytopenia, anemia with Hb \<9)~ * Patients receiving immunosuppressive treatments~ * Treatment by intramuscular corticoid, during the 3 months prior to the first administration of the trial treatment.~ * Treatment with non-steroidal anti-inflammatory drugs (more than 10 days consecutive to usual doses), opiates or oral steroids during the 15 days prior to treatment in the study.~ * Severe heart disease~ * Patients unable to comply with scheduled visits, for work or spend long periods away from their habitual residence.~ * Patients with active cancer or cancer diagnosed in the last five years.~ * Analytical Diagnosis Hepatitis B, C or HIV infection.~ * Pregnant or lactating.~ * People who are taking a drug in clinical investigation or participated in any investigational study clinic (with an authorized or not) within 30 days prior to randomization.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Platelet rich plasma (PRP) (Type: EXPERIMENTAL): 3 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
- control (Type: ACTIVE_COMPARATOR): needle tenotomy with lidocaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women during one of their first 3 IVF cycle attempts~* Women between the ages of 18-42.~* BMI (body mass index) of 18-35.~* AMH (Anti mullerian hormone) \> 1 ng/ml~* FSH˂ 20 IU/L.~* Informed consent.~Exclusion Criteria:~* Women with low ovarian response~* Previous enrollment in this study.~* AFC\>20~* E2 above 15,000 pmol/l at the trigger day.~* hypersensitive to Suprefact/Pregny/gonal F/Purigon/Menopur/progesterone, and/or their ingredients/components of the formulation~* primary ovarian failure~* pregnancy and breast-feeding~* active blood clots~* undiagnosed uterine or genital bleeding~* endometriosis~* uncontrolled hypertension;~* uncontrolled diabetes~* abnormal liver and kidney functions~* abnormal ECG, e.g. QT prolongation and torsades de pointes~* cancers/tumors, e.g. pituitary adenomas, ovarian cysts, etc.~* HIV, HBV and HCV infections~* low bone mineral density (BMD) and an increased risk of bone fracture, such as chronic alcohol and/or tobacco use, presumed or strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids~* suicidal tendency, history or disposition to seizures, state of confusion, clinically relevant psychiatric disorders, and brain lesions~* Use of an investigational drug or participation in an investigational study within 30 days prior to this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 41 Years
- Healthy Volunteers: t

Study Arms:
- Double trigger (Type: EXPERIMENTAL): Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
- control (Type: PLACEBO_COMPARATOR): Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent~* General good health~* Asthma or COPD~* Capable of understanding the requirements, risks, and benefits of study participation.~* Able to demonstrate proper metered-dose inhaler use and technique.~* Other inclusion criteria apply~Exclusion Criteria:~* History of life-threatening asthma or COPD that is defined for this protocol as an asthma or COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.~* Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of Screening Visit.~* Is being treated with a long-acting β2-agonist alone.~* Is currently being treated with Ventolin HFA.~* Any asthma or COPD exacerbation requiring oral corticosteroids within 2 months of Screening Visit. A subject must not have had any hospitalization for asthma or COPD within 4 months prior to Screening Visit.~* Historical or current evidence of a clinically significant non-asthmatic acute or chronic condition.~* Uncontrolled hypertension~* History of any adverse reaction to any component of the HFA-MDI formulation.~* Participation in any investigational drug study within the 30 days preceding the Screening Visit.~* Other exclusion criteria apply.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albuterol MDI (Type: None): All participants in this study will receive an albuterol MDI inhaler.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female aged 18 and above.~* The body mass index is in the range of 18.6-28.5 kg/m2 (including the critical value). The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg.~* The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG, breath test for alcohol, drug abuse test.~* The subjects have no family planning within 3 months and could select contraceptive method.~* Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.~Exclusion Criteria:~* Being allergy to the study medications, smoking, alcohol abuse.~* Participation in another clinical trial within 3 months.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Amlodipine (Type: ACTIVE_COMPARATOR): amlodipine reference formulation at a single dose of 10 mg
- Levamlodipine (Type: EXPERIMENTAL): levamlodipine test formulation at a single dose of 5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients with chronic hepatitis B meet the diagnostic criteria of China Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2015)~Exclusion Criteria:~* coinfection with other viruses including HCV, HDV, and HIV;~* syphilis antibody positive;~* co-exist other liver diseases including alcoholic liver disease, metabolic liver disease, fatty liver, drug induce liver injury, and autoimmune liver disease;~* complication of cirrhosis or liver cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Continuous interferon treatment group (Type: None): Patients with chronic hepatitis B treated with continuous interferon for 48 weeks
- Intermittent interferon treatment group (Type: None): patients with chronic hepatitis B treated with intermittent interferon for 48 weeks, in which interferon therapy was intermittent for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female children, 1 to 4 years of age at the time of first vaccination (up to but not including 5th birthday).~* Written/thumbprinted and witnessed informed consent obtained from the parents or legal guardians.~Exclusion Criteria:~* Major congenital defects or serious chronic illness.~* History of allergic reactions to vaccination or to any component of the Hiberix™, Prevnar® or Engerix-B™ vaccines.~* Chronic administration (defined as more than 14 days) of immuno-suppressants or other immune modifying drugs within six months prior to the first vaccine dose .~* Previous vaccination with an experimental vaccine or with hepatitis B vaccine in children equal to or more than 18 months of age.~* Simultaneous participation in any other clinical trial.~* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Planned administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. An exception, is the receipt of an EPI or licensed vaccine.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 or older,~* signed informed concern,~* within 2 hours of ICU admission,~* diagnosed alcohol withdrawal syndrome or alcohol withdrawal delirium by DSM IV criteria~Exclusion Criteria:~* younger than 18 or older than 75,~* history of use or withdrawal states of other psychoactive substances,~* general anesthesia during last 24 hours or known other sedatives use,~* severe neurologic disorder (traumatic brain injury, acute stroke, severe dementia),~* pregnancy or lactation,~* severe comorbidities (severe heart failure, acute myocardial infarction, heart rate \<50/min, glomerular filtration rate \< 30 ml/min, liver failure Child-Pugh class C),~* known allergy to the study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group D (Type: EXPERIMENTAL): Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
- Group C (Type: NO_INTERVENTION): Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with confirmed persistent or paroxysmal AF and suspected coronary artery disease who will undergo catheterization X-ray angiography~Exclusion Criteria:~1. Critically ill patients, patients on ventilators patients with hypotension, asthmatics, and other patients whose medical care or safety may be compromised from undergoing an MRI examination will be excluded.~2. Patients with claustrophobia will also be excluded since MRI is conducted in a closed environment.~3. Patients with contraindications to MRI (pacemaker, metal implants).~4. Pregnant subjects (or women who may become pregnant), minors, and prisoners will be excluded from this study.~5. Subjects are over 60 or have any suspicion of abnormal kidney function (a blood test to determine Glomerular filtration rate (GFR) will be performed prior to imaging. Subjects with GFR\<30 will be excluded from the study. This is standard practice for clinical scans in Radiology due to the extremely small but not negligible relationship between gadolinium contrast agent and nephrogenic systemic fibrosis in patients with severely impaired renal function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Regadenoson MRI (Type: EXPERIMENTAL): Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic and Pharmacokinetic Study of PL-ASA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female non-smoking subjects between the ages of 18 to 75 years inclusive, without known medical conditions requiring treatment~* Consumes on average no more than 2 alcoholic drinks per day for 30 days prior to study~Exclusion Criteria:~* Abnormal baseline laboratory results~* Current prescribed use of aspirin, warfarin or other anticoagulants~* Use of other specific medications within 2 weeks of study start~* History of certain medical conditions~* Subject's platelets are unresponsive to arachidonic acid, as defined as \<60% of aggregation as measured by light transmittance aggregometry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PL-ASA capsule, then EC-ASA tablet (Type: OTHER): PL-ASA capsule 81 mg, then crossover to EC-ASA tablet 81 mg
- EC-ASA tablet, then PL-ASA capsule (Type: ACTIVE_COMPARATOR): EC-ASA tablet 81 mg, then crossover to PL-ASA capsule 81 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete